IPO registrations (S-1, F-1) · Registrants
MiNK Therapeutics, Inc.
- SEC CIK
- 1840229 · filings on EDGAR ↗
- Former names
- AgenTus Therapeutics, Inc. (2021–2021); AgenTus Therapeutics, Inc. (2021–2021)
- Registration
- Form S-1, first filed 2021-09-14, last 2021-10-12; 1 initial registration, 1 amendment
- Outcome
- Final prospectus filed 2021-10-15; declared effective 2021-10-14
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 149 FIFTH AVENUE, SUITE 500, New York, NY 10010
- Ticker
- INKT (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- MiNK Therapeutics, Inc. on the corporate pages
Offering terms
- Proposed price range
- $12.00–$14.00 per share (S-1/A filed 2021-10-12)
- Final price
- $12.00 per share, within the range (424B4 filed 2021-10-15, an initial public offering)
- Shares sold
- 3,333,334
- Gross proceeds
- $40,000,008 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol INKT
- Lead underwriters
- Evercore; William Blair (1,333,334 shares)
- Syndicate
- B. Riley Securities (333,333); Baird (333,333)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: MINK THERAPEUTICS, INC. Fuzzy (name and state)
- Federal award recipient: MINK THERAPEUTICS INC Fuzzy (name and state)
- SEC filer: MiNK Therapeutics, Inc. EXACT (CIK (EXACT))
- Person page: Garo H Armen Phd Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 5
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2021-09-14 | S-1 | S-1 (registration) | MiNK Therapeutics, Inc. | 0001193125-21-271914 ↗ |
| 2021-10-12 | S-1/A | S-1/A (amendment) | MiNK Therapeutics, Inc. | 0001193125-21-296215 ↗ |
| 2021-10-14 | EFFECT | EFFECT (declared effective) | MiNK Therapeutics, Inc. | 9999999995-21-003881 ↗ |
| 2021-10-15 | 424B4 | 424B4 (final prospectus) | MiNK Therapeutics, Inc. | 0001193125-21-300184 ↗ |
| 2022-11-08 | EFFECT | EFFECT (declared effective) | MiNK Therapeutics, Inc. | 9999999995-22-003237 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021-10-12 | S-1/A | registration statement | $12.00–$14.00 | 4,000,000 | - | Nasdaq INKT | 4 | primary document; range, shares headline, cover names 4 | document ↗ | |
| 2021-10-15 | 424B4 | final prospectus | $12.00 | 3,333,334 | $40,000,008 | Nasdaq INKT | 4 | primary document; price sentence, shares headline, proceeds table, underwriting table 3, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| AGENUS INC | TenPercentOwner | 11 | 2021–2023 | ||
| ARMEN GARO H | Director | 6 | 2021–2023 | person page Fuzzy | |
| Baldoni John | Director | 8 | 2021–2023 | ||
| Behner Peter | Director | 21 | 2021–2026 | ||
| Buell Jennifer | Director,Officer; Officer | Chief Executive Officer; See Remarks | 11 | 2021–2026 | |
| Corvese Brian | Director | 21 | 2021–2026 | ||
| FLAMENBAUM WALTER MD | Director | 1 | 2021 | ||
| KLASKIN CHRISTINE M | Officer | Treasurer | 1 | 2021 | |
| Ryan Barbara | Director | 24 | 2021–2026 | ||
| van Dijk Marcus Antonius | Officer | Chief Scientific Officer; Chief Technology Officer | 5 | 2021–2024 | |
| WIINBERG ULF | Director | 22 | 2021–2026 | ||
| Kadlec Robert Peter | Director | 7 | 2024–2025 | ||
| Holcomb John Bradley | Director | 4 | 2025–2026 | ||
| Charette Austin | Officer | Principal Accounting Officer | 1 | 2026 | |
| Orilall Melissa | Officer | Principal Financial Officer | 1 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | MINK THERAPEUTICS, INC. | NY | State business registries | name and state |
| Federal award recipient | MINK THERAPEUTICS INC | NY | Federal spending (USAspending) | name and state |
| IPO registrant | Protagenic Therapeutics, Inc.\new | NY | IPO registrations (S-1, F-1) | same street address and ZIP code, 149 FIFTH AVE STE 500 10010 (FUZZY: a shared address, not proof of a shared organization) |
| Patent assignee | MiNK Therapeutics, Inc. | NY | Patents (USPTO) | name and state |
| SEC filer | MiNK Therapeutics, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Person page | Garo H Armen Phd | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), NY first:
- Acorda Therapeutics, Inc. NY
- BRAINSTORM CELL THERAPEUTICS INC. NY
- ANAVEX LIFE SCIENCES CORP. NY
- CytRx Oncology Corp NY
- Omrix Biopharmaceuticals, Inc. NY
- Protara Therapeutics, Inc. NY
- COGNITION THERAPEUTICS INC NY
- Bavarian Nordic A/S / ADR NY
- Qrons Inc. NY
- Prevail Therapeutics Inc. NY
In other datasets, the same topic (Health) in NY:
- Nonprofit: AABR FOUNDATION INC (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health